Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 20/20 | 1.00 |
| ▸ | DRD2 | P14416 | 15/20 | 1.00 |
| ▸ | DRD3 | P35462 | 14/20 | 1.00 |
| ▸ | DRD5 | P21918 | 4/20 | 1.00 |
| ▸ | F3 | P13726 | 3/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.91 |
| ▸ | HTR1A | P08908 | 1/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | CASP1 | P29466 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stepholidine SCHEMBL10001965 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| Stepholidine SCHEMBL10001966 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| Stepholidine SCHEMBL29414100 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| Stepholidine SCHEMBL29943869 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| Corydalmine SCHEMBL21192512 | 0.94 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| Corydalmine SCHEMBL12667453 | 0.94 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| Corydalmine SCHEMBL29243055 | 0.93 | DRD1 (0.98) | DRD1DRD2DRD3DRD5F3 | |
| SCHEMBL14703846 | 0.93 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| SCHEMBL680031 | 0.93 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| SCHEMBL29561422 | 0.93 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687856-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS Therapeutics, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-06-05 | — | — | US | claimed |
| US-20240366525-A1 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC | 2024-11-07 | — | — | US | claimed |
| WO-2024229159-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | claimed |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-08-01 | — | — | US | claimed |
| EP-4378532-A2 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2024-06-05 | — | — | EP | claimed |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-11-02 | — | — | US | claimed |
| US-20230172916-A1 | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERINE ALKALOID AND METHOD FOR MANUFACTURING SAME | ELEONOR (BE) | 2023-06-08 | — | — | US | claimed |
| US-11666547-B2 | Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1) | NORTHWESTERN UNIVERSITY (US) | 2023-06-06 | — | — | US | claimed |
| WO-2013028909-A1 | COMBINATION THERAPY FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | WO | claimed |
| WO-2012158492-A2 | TREATMENT AND MANAGEMENT OF CNS DISORDERS | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-11-22 | — | — | WO | claimed |
| WO-2012087377-A1 | METHODS OF PRODUCING STABILIZED SOLID DOSAGE PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS | MALLINCKRODT LLC (US) | 2012-06-28 | — | — | WO | claimed |
| US-20110287095-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-11-24 | — | — | US | claimed |
| WO-2011139983-A1 | NOVEL METHODS OF USE OF TETRAHYDROBERBERINE (THB) | CATHOLIC HEALTHCARE WEST (US) | 2011-11-10 | — | — | WO | claimed |
| WO-2011087765-A2 | METHODS OF PRODUCING STABILIZED SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS | MALLINCKRODT INC. (US) | 2011-07-21 | — | — | WO | claimed |
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-06-23 | — | — | US | claimed |
| WO-2011041470-A2 | SUSTAINED-RELEASE OPIATE AND OPIATE DERIVATIVE COMPOSITIONS | MALLINCKRODT INC. (US) | 2011-04-07 | — | — | WO | claimed |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | MALLINCKRODT INC. (US) | 2011-03-31 | — | — | US | claimed |
| US-5547956-A | ADMINISTERING TO PATIENT ACONITANE DERIVATIVES AND THEIR INORGANIC SALTS AND TETRAHYDROPROTOBERBERINE DERIVATIVES; SIDE EFFECT REDUCTION | Qu, Yueqian (CN) | 1996-08-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | DRD1 963/4885DRD2 1084/4885DRD3 1370/4885 |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD1 4883/4885DRD2 4882/4885DRD3 4873/4885 |
| US-20110287095-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | DRD1 963/4885DRD2 1084/4885DRD3 1370/4885 |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | OPRL1, OPRK1, OPRM1 | DRD1 213/4885DRD2 85/4885DRD3 57/4885 |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD1 4882/4885DRD2 4879/4885DRD3 4860/4885 |
| US-11666547-B2 | Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1) | SLC6A1, SLC6A3, SLC6A13 | DRD1 11/4885DRD2 18/4885DRD3 27/4885 |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD1 4882/4885DRD2 4879/4885DRD3 4860/4885 |
| US-20230172916-A1 | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERINE ALKALOID AND METHOD FOR MANUFACTURING SAME | MANBA, CROCC, MAN2A1 | DRD1 1370/4885DRD2 1092/4885DRD3 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.